Compare ELA & IPHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ELA | IPHA |
|---|---|---|
| Founded | 1965 | 1999 |
| Country | United States | France |
| Employees | N/A | 163 |
| Industry | Consumer Specialties | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 619.2M | 189.5M |
| IPO Year | 1995 | N/A |
| Metric | ELA | IPHA |
|---|---|---|
| Price | $25.97 | $1.76 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 4 |
| Target Price | ★ $16.50 | $5.75 |
| AVG Volume (30 Days) | 121.3K | ★ 134.2K |
| Earning Date | 05-06-2026 | 03-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 115.38 | N/A |
| EPS | ★ 0.34 | N/A |
| Revenue | ★ $241,021,362.00 | N/A |
| Revenue This Year | N/A | $180.36 |
| Revenue Next Year | $22.54 | N/A |
| P/E Ratio | $80.62 | ★ N/A |
| Revenue Growth | ★ 33.62 | N/A |
| 52 Week Low | $5.33 | $1.18 |
| 52 Week High | $27.59 | $2.63 |
| Indicator | ELA | IPHA |
|---|---|---|
| Relative Strength Index (RSI) | 63.23 | 55.75 |
| Support Level | $11.34 | $1.72 |
| Resistance Level | $26.96 | $2.32 |
| Average True Range (ATR) | 1.77 | 0.20 |
| MACD | 0.12 | -0.01 |
| Stochastic Oscillator | 50.24 | 44.62 |
Envela Corp is a provider of recycling and re-commerce services at the forefront of the circular economy. It operates through two segments, Consumer and Commercial Services. The Consumer segment, which generates key revenue for the company, predominantly buys to resell or recycle luxury hard assets like jewelry, diamonds, gemstones, fine watches, rare coins, and related collectibles, precious-metal bullion products, gold, silver, and other precious metals. The Commercial Services segment provides asset-disposition solutions to government agencies, middle-market firms, corporations, and other organizations.
Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. The company's approach includes therapeutic modalities such as monoclonal antibodies, multispecific NK cell engagers through its ANKET platform, and antibody-drug conjugates (ADC). Its portfolio includes lacutamab, which is being studied for cutaneous T-cell lymphomas and peripheral T-cell lymphomas, and monalizumab, which is being developed in collaboration with AstraZeneca for non-small cell lung cancer. The company's revenue mainly consists of revenues from collaboration and licensing agreements and government financing for research expenditure in the form of research tax credits, as well as other grants.